Is Pfizer the Cure for a Weak Market? My friends, we are in tumultuous times.Markets are seemingly in freefall.
During these times, the need for information surges.
Blog viewershipthrough the roof.
Google (GOOG) queries on all things financialpopping.
Barronsa bear on...
New study reveals Caduet two-in-one pill dramatically improves patient adherence -Patient adherence essential in reducing risk of cardiovascular disease- KIRKLAND, QC, July 7 /CNW/ - Despite the proven benefits of blood pressure and cholesterol medications for the prevention of cardiovascular events(1) and guidelines...
New study reveals CADUET two-in-one pill dramatically improves patient adherence Attention Health/Lifestyle Editors -Patient adherence essential in reducing risk of cardiovascular disease- KIRKLAND, QC, July 7 According to a new study, Caduet Adherence Related PharmacoEconomic Value Model (CARPE-V), published in...
A Professional Thought Leader Analysis of Non-Interventional Cardiology and Major Industry Drugs DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ce5f70/thought_leader_ins) has announced the addition of the 'Thought Leader Insight & Analysis: Non-Interventional Cardiology' report...
Fixed-Dose Combination Statins--Is there More Good than Harm? FIXED-DOSE COMBINTATION STATINS, STATINS, LI DISORDERS, RANDOMIZED TRIALS, CARDIOVASCULAR DISEASE Contact Information Available for logged-in reporters only Description Controversies surrounding fixed-dose combination statins have drawn...
Examine the Lipitor Market Analysis and Forecasts Report, 2007-2012, 2017 and 2023 1 Executive Summary 1.1 Lipitor Was the World's Best Selling Drug In 2006 1.2 Lipitor Will Face Strong Competition After Patent Expiration In Key Markets 1.3 Lipitor Is Embroiled In Patent Challenges With Ranbaxy 2 Overview of Lipitor ...
Examine the Lipitor Market Analysis and Forecasts Report, 2007-2012, 2017 and 2023 -- Reportlinker.com announces that a new market research report related to the Cardiovascular diseases industry is available in its catalogue.In 2006, Pfizer's Lipitor (atorvastatin) generated global revenues of $13.6bn, making it the...
What drug firms want, they get L ike book publishers, song writers, and music and movie companies, the makers of pharmaceuticals want to see 'intellectual rights' protected - and if they all had their way, trademarks and patents would last for an eternity.Last week, it...
Walgreen quarterly profit rises 2 percent CHICAGO (Reuters) - Walgreen Co on Monday posted a 2 percent increase in quarterly profit as a weak U.S.economy and slowing growth in demand for prescription drugs muted sales.
But the company also said it was on pace to open more...
FDA Stings Pharma, Big and Small The first shock came after Merck (MRK) and Schering-Ploughs (SGP) Vytorin ENHANCE study.Surrogate markers like cholesterol counts would no longer be enough to garner marketing approval.
Genzyme (GENZ) and Isis (ISIS) received the first...
Pfizer and Ranbaxy Settle Lipitor Patent Litigation Worldwide NEW YORK - Pfizer Inc.announced in a Wednesday press release that it has entered into an agreement with generics manufacturer Ranbaxy Laboratories Ltd.
of India and certain of its affiliates to settle substantially all their patent...
Pfizer-Ranbaxy deal might signal trend This article is FREE access as part of MIP Week, a weekly email newsletter written by the editors of Managing Intellectual Property magazine.Take a two week trial to MIP and find many more related articles.
Eklavya Gupte, London This...
Pfizer reaches settlement to delay generic Lipitor Pfizer bought some extra time for its blockbuster cholesterol drug Lipitor (atorvastatin) by reaching a settlement with Ranbaxy Laboratories delaying the US launch of a generic version of the world's top selling pharmaceutical brand.Under...
Patent settlement fails to enthuse Ranbaxy, shares fall 8 pc At the end of the day's trading the scrip pared the morning gains to close at Rs 552.25, down Rs 45.95 or 7.68 per cent.In the early morning trade, the scrip had touched a 52-week high of Rs 613.70, up 2.59 per cent compared to previous...
Deal delays rival copy of Lipitor Generic will be kept off U.S.market an extra 20 months in boon to Pfizer Share this article: Pfizer Inc.
and India's Ranbaxy Laboratories Ltd.
have agreed to keep copies of the cholesterol pill Lipitor off the U.S.
market an extra...
Pfizer in patent, litigation settlement with Ranbaxy over generic Lipitor BOSTON (MarketWatch) -- Pfizer Inc.shares climbed nearly 5% at one point Wednesday, gaining as the drugmaker reached an agreement that would allow India's Ranbaxy Laboratories Ltd.
to market a generic version of Pfizer's blockbuster...
Pfizer, Ranbaxy Settle Lipitor Fight Pfizer has entered into an agreement with generics manufacturer of India to settle all their patent litigation worldwide involving Lipitor.Under the terms of the agreement, Ranbaxy will have a license to sell generic versions of Lipitor...
Pfizer and Ranbaxy Settle Lipitor Patent Litigation Worldwide - Pfizer Inc announced today that it has entered into an agreement with generics manufacturer Ranbaxy Laboratories Ltd.of India and certain of its affiliates to settle substantially all their patent litigation worldwide involving Lipitor,...
Pfizer & Ranbaxy settle Lipitor patent litigation worldwide Pfizer Inc, has entered into an agreement with generics manufacturer Ranbaxy Laboratories Ltd.of India and certain of its affiliates to settle substantially all their patent litigation worldwide involving Lipitor, the world's most...
Pfizer and Ranbaxy Settle Lipitor Patent Litigation Worldwide NEW YORK-- (BUSINESS WIRE) -- Pfizer Inc announced today that it has entered into an agreement with generics manufacturer of India and certain of its affiliates to settle substantially all their patent litigation worldwide involving Lipitor,...
Pfizer settles patent dispute Lipitor agreement pushes back generic competition Pfizer Inc.has earned a little extra time to develop products to replace its best-selling cholesterol drug Lipitor, announcing Wednesday a patent-litigation settlement with an Indian...
Ranbaxy looks strong on long-term charts Bookmark / Share More Save Write to Editor MUMBAI: Shares of pharmaceutical major Ranbaxy Laboratories ended sharply lower on Thursday after brokerages came out with negative reports on Lipitor (Atorvastation molecule) settlement case with...
Pfizer deal may hold off generics Settlement with Ranbaxy extends patent of Lipitor Star-Ledger Staff Pfizer announced yesterday it was settling an epic legal battle with the Indian drugmaker Ranbaxy Laboratories that will keep generic versions of the best-selling...
STOCKWATCH Ranbaxy drops 5.5 pct on patent settlement with Pfizer UPDATE (Update adds analyst comment, details and updates share price) MUMBAI (Thomson Financial) - Ranbaxy Laboratories Ltd.was trading over 5 percent lower after India's largest pharma company agreed to bury the hatchet with US giant Pfizer Inc...
STOCKWATCH Ranbaxy drops 5.5 pct on patent settlement with Pfizer UPDATE Under the terms of the agreement, Ranbaxy will have a license to sell generic versions of Lipitor and Caduet in the United States, as of Nov.30, 2011.
Ranbaxy will have exclusive marketing rights for 180 days.
Ranbaxy will also...
